Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Chemotherapy. David Geffen School of Medicine at UCLA, Los Angeles, CA, United States



Survival: 10.5 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Los Angeles, CA
   
Hospital: David Geffen School of Medicine at UCLA
   
Journal: Link
   
Date: 8/2014

Description:
Patients:
This phase 3 study involved non-small cell lung cancer patients who had received prior platinum-based chemotherapy and were divided into two separate treatment groups. Group A consisted of 628 patients with a median age of 62 years; 67% were male. Group B had 625 patients with a median age of 61 years; 66% were male.

Treatment:
Patients in group A received chemotherapy with docetaxel and biologic therapy with ramucirumab (a monoclonal antibody that blocks the VEGFR-2 protein).

Patients in group B received chemotherapy with docetaxel and a placebo.

Toxicities:
Treatment-related deaths due to hemorrhage, infection, cardiac events, respiratory problems, kidney failure and pulmonary embolism were reported for group A. Grade 3 or higher fatigue, mucosal inflammation, and diarrhea were also reported.

Treatment-related deaths due to hemorrhage, infection, cardiac events, respiratory problems, and stroke were reported for group B. Grade 3 or higher fatigue, shortness of breath, and vomiting were also reported.

Results:
The median overall survival rates for groups A and B were 10.5 and 9.1 months, respectively.

Support:
This study was supported by Eli Lilly.

Correspondence: Dr. Edward B Garon; email: egaron@mednet.ucla.edu

E-mail to a Friend Email Physician More Information